Show simple item record

dc.contributor.authorSaderi, Len_US
dc.contributor.authorPuci, Men_US
dc.contributor.authorDi Lorenzo, Ben_US
dc.contributor.authorCentis, Ren_US
dc.contributor.authorD'Ambrosio, Len_US
dc.contributor.authorAkkerman, OWen_US
dc.contributor.authorAlffenaar, J-WCen_US
dc.contributor.authorCaminero, JAen_US
dc.contributor.authorChakaya, JMen_US
dc.contributor.authorDenholm, JTen_US
dc.contributor.authorKurhasani, Xen_US
dc.contributor.authorOng, CWMen_US
dc.contributor.authorRendon, Aen_US
dc.contributor.authorSilva, DRen_US
dc.contributor.authorTiberi, Sen_US
dc.contributor.authorZenner, Den_US
dc.contributor.authorCabibbe, AMen_US
dc.contributor.authorMigliori, GBen_US
dc.contributor.authorSotgiu, Gen_US
dc.date.accessioned2022-09-22T13:42:53Z
dc.date.available2022-07-15en_US
dc.date.issued2022-07-28en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/80668
dc.description.abstractINTRODUCTION: No previous systematic reviews have comprehensively investigated the features of Xpert MTB/XDR and other rapid tests to diagnose pre-XDR/XDR-TB. The aim of this systematic review is to assess existing rapid diagnostics for pre-XDR/XDR-TB from a point-of-care perspective and describe their technical characteristics (i.e., sensitivity, specificity, positive and negative predictive values). METHODS: Embase, PubMed, Scopus, and Web of Science were searched to detect the articles focused on the accuracy of commercially available rapid molecular diagnostic tests for XDR-TB according to PRISMA guidelines. The analysis compared the diagnostic techniques and approaches in terms of sensitivity, specificity, laboratory complexity, time to confirmed diagnosis. RESULTS: Of 1298 records identified, after valuating article titles and abstracts, 97 (7.5%) records underwent full-text evaluation and 38 records met the inclusion criteria. Two rapid World Health Organization (WHO)-endorsed tests are available: Xpert MTB/XDR and GenoType MTBDRsl (VER1.0 and VER 2.0). Both tests had similar performance, slightly favouring Xpert, although only 2 studies were available (sensitivity 91.4-94; specificity 98.5-99; accuracy 97.2-97.7; PPV 88.9-99.1; NPV 95.8-98.9). CONCLUSIONS: Xpert MTB/XDR could be suggested at near-point-of-care settings to be used primarily as a follow-on test for laboratory-confirmed TB, complementing existing rapid tests detecting at least rifampicin-resistance. Both Xpert MTB/XDR and GenoType MTBDRsl are presently diagnosing what WHO defined, in 2021, as pre-XDR-TB.en_US
dc.languageeng spaen_US
dc.relation.ispartofArch Bronconeumolen_US
dc.subjectDrug susceptibility testen_US
dc.subjectGenoType MTBDRslen_US
dc.subjectLine probe assayen_US
dc.subjectMDR-TBen_US
dc.subjectPre-XDRen_US
dc.subjectSensitivityen_US
dc.subjectSpecificityen_US
dc.subjectTuberculosisen_US
dc.subjectXDR-TBen_US
dc.subjectXpert MTB/XDRen_US
dc.titleRapid Diagnosis of XDR and Pre-XDR TB: A Systematic Review of Available Tools.en_US
dc.typeArticle
dc.identifier.doi10.1016/j.arbres.2022.07.012en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35945071en_US
pubs.notesNot knownen_US
pubs.publication-statusPublished onlineen_US
dcterms.dateAccepted2022-07-15en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record